medigraphic.com
ISSN 1561-3070 (Electronic)

2014, Number 1

<< Back Next >>

Rev Cub Oftal 2014; 27 (1)

Functional and anatomical results of the recurrent retinal detachment surgery caused by proliferative vitreoretinopathy

Garcés FA

Language: Spanish
References: 35
Page: 16-28
PDF size: 130.88 Kb.


ABSTRACT

Objective: to assess the functional and anatomical results of surgery for recurrent retinal detachment caused by proliferative vitreoretinopathy.
Methods: retrospective, observational and descriptive study of a case series of 17 eyes diagnosed with recurrent retinal detachment caused by proliferative vitreo retinopathy were operated on in the period of January 2010 through December 2011. The patients were followed up for at least 3 months after the last surgery. Functional outcomes were assessed with best corrected visual acuity and the anatomical ones through the retinal and macular reattachment.
Results: a total of 25 reoperations were performed, a range of 1 to 3. Retinotomy and retinectomy were performed in 52 % of surgeries, most of them with an area less than 180° (84,6 %). The most frequently used tamponade was silicone oil (23,92 %). The mean postoperative best corrected visual acuity was 1,28 logMAR, improving in 58,8 % of eyes and being lower than 1,5 logMAR in 90 % of them. The retinal reattachment succeeded in 82,3 % (14 eyes). Macular reattachment occurred in 100 % of eyes.
Results: a total of 25 reoperations were performed, a range of 1 to 3. Retinotomy and retinectomy were performed in 52 % of surgeries, most of them with an area less than 180° (84,6 %). The most frequently used tamponade was silicone oil (23,92 %). The mean postoperative best corrected visual acuity was 1,28 logMAR, improving in 58,8 % of eyes and being lower than 1,5 logMAR in 90 % of them. The retinal reattachment succeeded in 82,3 % (14 eyes). Macular reattachment occurred in 100 % of eyes.
Conclusions: surgical treatment of the recurrent retinal detachment caused by vitreoretinal proliferation requires different surgical options to achieve the final retinal reattachment and visual improvement in highly complex cases.


REFERENCES

  1. Peter A. Campochiaro. The Pathogenesis of proliferative Vitreoretinopathy. En: Ryan SJ, Wilkinson CP. Retina. St Louis, Elsevier Mosby Ed. 2006. Cap 131. p. 2235-40.

  2. John T. Proliferative Vitreoretinopathy. En: Ryan SJ, Wilkinson C.P. Retina. St Louis, Elsevier Mosby Ed. 2006. Cap 135. p. 2283-2309.

  3. Blumenkranz MS, Hartzer MK. The mechanism of action of drugs for the treatment of vitreoretinal scarring. En: Ryan SJ , Wilkinson CP. Retina. St Louis, Elsevier Mosby Ed; 2006. Cap. 132. p. 2241-53.

  4. Rodríguez de la Rúa E, Martínez V, Aragón J. Factores clínicos de riesgo para el desarrollo de la vitreorretinopatía proliferante postquirúrgica. Estudio prospectivo. Arch Soc Esp Oftalmol [Internet]. 2003 (citado 5 de diciembre de 2013);78(2):91-8. Disponible en: http://www.vision-research.eu/fileadmin/user_upload/researcher/p/ pastor-jose_carlo-cv_full.pdf

  5. Lleò A, Campos R, López F, Sánchez G, Hernández FJ, Navarro Palop C. Factores clínicos de riesgo de la vitreorretinopatía proliferativa después de la cirugía del desprendimiento de retina. Arch Soc Esp Oftalmol. 2000;75(11):741-50.

  6. Blumenkranz MS, Azen SP, Aaberg T, Boone DC, Lewis H, Radtke N, et al. Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy. Silicone study report 5. The silicone study group. Am J Ophthalmol 1993;116(5):557-64.

  7. Sociedad Española de Retina y Vitreo. Fracaso y recidiva del desprendimiento de retina regmatógeno con y sin proliferación vitreorretiniana. Tratamiento del desprendimiento de retina. Guías de Práctica Clínica [Internet]. 2010 (citado 5 de diciembre de 2013). Disponible en: http://www.serv.es

  8. Machemer R, Aaberg TM, Freeman HM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159-65.

  9. Schulze Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual Acuities «Hand Motion» and «Counting Fingers» can be quantified with the Freiburg Visual Acuity Test. Invest Ophthalmol Vis Sci. 2006;47(3):1236-40.

  10. Kon CH, Asaria RH, Occteston NL, Kham PT, Aylward GW. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol. 2000 May;84(5):506-11.

  11. Khaled AG. Relaxing retinotomies and retinectomies in the management of retinal detachment with severe proliferative vitreoretinopathy. Clin Ophthalmol. 2010;4:1107-14.

  12. McCuen BW. Retinal Physician. Relaxing retinectomy in PVR surgery. Learn why this surgeon is doing fewer vitrectomies. Retinal Physician [Internet]. 2004 (citado 5 de diciembre de 2013). Disponible en: http://www.retinalphysician.com/articleviewer.aspx?articleid=100041

  13. Tseng JJ, Barile GR, Schiff WM, Akar Y, Vidne-Hay O, Chang S. Influence of relaxing retinotomy on surgical outcomes in proliferative vitreoretinopathy. Am J Ophthalmol. 2005;140(4):628-36.

  14. Quiram PA, González CR, Hu W. Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Ophthalmology. 2006;113(11):204-17.

  15. Grigoropoulos VG, Benson S, Bunce C, Charteris BG. Functional outcome and prognostic factors in 304 eyes managed by retinectomy. Graefes Arch Clin Exp Ophthalmol. 2007;245(5):641-9.

  16. Morse LS, McCuen BW, Machemer R. Relaxing retinotomies. Analysis of anatomic and visual results. Ophthalmology. 1990;97(5):642-7.

  17. Han DP, Rychwalski PJ, Mieler WF, Abrams GW. Management of complex retinal detachment with combined relaxing retinotomy and intravitreal perfluoro-n-octane injection. Am J Ophthalmol. 1994;118(1):24-32.

  18. Blumenkranz MS, Azen SP, Aaberg T. Relaxing retinotomy with silicone oil or longacting gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 5. The Silicone Study Group. Am J Ophthalmol. 1993;116(5):557-64.

  19. Tseng JJ, Schiff MW, Barile GR. Influence of posoperative lens status on intraocular pressure in proliferative vitreoretinopathy. Am J Ophthalmol. 2009;147(5):875-85.

  20. Turgut B, Uyar F, Ustundag B, Celiker U, Akpolat N, Demir T. The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy. Retina. 2012;32(2):232-41.

  21. Nassar K, Lüke J, Lüke M, Kamal M, Abd El-Nabi E, Soliman M. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Arch Clin Exp Ophthalmol. 2011;249(11):1649-60.

  22. Lin ML, Li YP, Li ZR, Lin JX, Zhou XL, Liang D. Macrophages acquire fibroblast characteristics in a rat model of proliferative vitreoretinopathy. Ophthalmic Res. 2011; 45(4):180-90.

  23. Zhong N, Da X, Xue B, Yi X. Effect of genistin on proliferative vitreoretinopathy. 2010;35(7):749-53.

  24. Sundaram V, Barsam A, Virgili G. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev. 2010;(7):CD006421.

  25. Ali A, Rosenbaum JT. Use of methotrexate in patients with uveitis. Clinical and experimental rheumatology. 2010;28(5):145-50.

  26. Samson CM, Waheed N, Baltatzis S, Foster CS. Metothotrexate therapy for chronic noninfectious uveitis: an anlysis of a case series of 160 patients. Ophthalmology. 2001;108(6):113-49.

  27. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32(2):362-5.

  28. Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol. 2005;89(7):806-8.

  29. Muñoz-Fernández S, García-Aparicio AM. Methotrexate: an option for preventing the recurrence of acute anterior uveitis. Eye [Internet]. 2009 (citado 5 de diciembre de 2013);23:1130-3. Disponible en: http://www.readcube.com/articles/10.1038/eye.2008.198

  30. Sallam A, Taylor SR, Lightman S. Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol. 2011;22(6):517-22.

  31. Modorati G, Miserocchi E. Intravitreal injection therapy in the treatment of noninfectious uveitis. Dev Ophthalmol. 2012;51(2):110-21.

  32. Hardwing PW, Pulido JS, Bakri SJ. The safety of intraocular methotrexate in silicone filled eyes. Retina. 2008;28(8):1082-6.

  33. Gupta B, Mokete B, Laidlaw DA, Williamson TH. Severe folding of the inferior retina after relaxing retinectomy for proliferative vitreoretinopathy. Eye. 2008;22(12):151-79.

  34. Kolomeyer A, Grigorian R, Mostafavi D, Bhagat N, Zarbin M. 360° Retinectomy for the Treatment of Complex Retinal Detachment. Retina. 2011;31(2):266-74.

  35. Tsui I, Schubert HD. Retinotomy and silicone oil for detachments complicated by anterior inferior proliferative vitreoretinopathy. Br J Ophthalmol. 2009;93(9):1228-33.




2020     |     www.medigraphic.com